Phase II Non-Randomized Pre-Surgical Study Evaluating Sunitinib in Patients with Metastatic Renal Cell Carcinoma (RCC) Who Are Eligible for Cytoreductive Nephrectomy
Latest Information Update: 08 Oct 2024
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 16 Jun 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2025.
- 16 Jun 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2025.
- 10 Oct 2022 Planned End Date changed from 30 Jun 2022 to 30 Jun 2023.